PL3642181T3 - Sposób wytwarzania substancji pośredniej pochodnej 4-metoksypirolowej - Google Patents

Sposób wytwarzania substancji pośredniej pochodnej 4-metoksypirolowej

Info

Publication number
PL3642181T3
PL3642181T3 PL18821303T PL18821303T PL3642181T3 PL 3642181 T3 PL3642181 T3 PL 3642181T3 PL 18821303 T PL18821303 T PL 18821303T PL 18821303 T PL18821303 T PL 18821303T PL 3642181 T3 PL3642181 T3 PL 3642181T3
Authority
PL
Poland
Prior art keywords
preparing intermediate
methoxypyrrole derivative
methoxypyrrole
derivative
preparing
Prior art date
Application number
PL18821303T
Other languages
English (en)
Inventor
Jeong-Taek SHIN
Jeong Hyun Son
Seung Chul Lee
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of PL3642181T3 publication Critical patent/PL3642181T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18821303T 2017-06-21 2018-06-21 Sposób wytwarzania substancji pośredniej pochodnej 4-metoksypirolowej PL3642181T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020170078745A KR102233455B1 (ko) 2017-06-21 2017-06-21 4-메톡시피롤 유도체의 중간체 제조 방법
EP18821303.7A EP3642181B1 (en) 2017-06-21 2018-06-21 Method for preparing intermediate of 4-methoxypyrrole derivative
PCT/KR2018/006989 WO2018236153A1 (en) 2017-06-21 2018-06-21 Method for preparing intermediate of 4-methoxypyrrole derivative

Publications (1)

Publication Number Publication Date
PL3642181T3 true PL3642181T3 (pl) 2022-02-14

Family

ID=64735783

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18821303T PL3642181T3 (pl) 2017-06-21 2018-06-21 Sposób wytwarzania substancji pośredniej pochodnej 4-metoksypirolowej

Country Status (30)

Country Link
US (2) US11345660B2 (pl)
EP (1) EP3642181B1 (pl)
JP (1) JP6799178B2 (pl)
KR (1) KR102233455B1 (pl)
CN (1) CN110582482B (pl)
AU (1) AU2018288933B2 (pl)
CA (1) CA3061713C (pl)
CL (1) CL2019003450A1 (pl)
CO (1) CO2019012689A2 (pl)
DO (1) DOP2019000291A (pl)
EC (1) ECSP19081847A (pl)
ES (1) ES2901701T3 (pl)
HR (1) HRP20211819T1 (pl)
HU (1) HUE057666T2 (pl)
JO (1) JOP20190265B1 (pl)
MA (1) MA49472B1 (pl)
MX (1) MX391715B (pl)
MY (1) MY188800A (pl)
NZ (1) NZ758770A (pl)
PE (1) PE20210151A1 (pl)
PH (1) PH12019502865A1 (pl)
PL (1) PL3642181T3 (pl)
PT (1) PT3642181T (pl)
RS (1) RS62564B1 (pl)
RU (1) RU2737470C1 (pl)
SA (1) SA519410407B1 (pl)
SG (1) SG11201911164WA (pl)
SI (1) SI3642181T1 (pl)
TN (1) TN2019000301A1 (pl)
WO (1) WO2018236153A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
US10789690B2 (en) * 2018-03-07 2020-09-29 Adobe Inc. Masking non-public content
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN109867617A (zh) * 2019-04-03 2019-06-11 南京格亚医药科技有限公司 一种4-甲氧基吡咯中间体的制备方法
CN112094219B (zh) * 2020-09-10 2022-08-05 广东莱佛士制药技术有限公司 一种制备钾离子竞争性阻滞剂中间体的方法
CR20250335A (es) 2023-02-15 2025-09-23 Daewoong Pharmaceutical Co Ltd Procedimiento de fabricación de derivados de 4-metoxipirrol
CN117326961B (zh) * 2023-09-27 2024-05-03 安徽峆一药业股份有限公司 一种非苏拉赞中间体的绿色合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
KR101178747B1 (ko) * 2004-09-30 2012-09-03 다케다 야쿠힌 고교 가부시키가이샤 프로톤 펌프 저해제
HRP20110473T1 (hr) 2005-08-30 2011-07-31 Takeda Pharmaceutical Company Limited Supstituirani derivati 1-heterociklilsulfonil, 2-aminometil, 5-(hetero)-aril 1-h-pirola kao inhibitori kiselinske sekrecije
MX2009008255A (es) * 2007-02-02 2009-08-12 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos taar1.
JP2011523633A (ja) * 2008-05-08 2011-08-18 ブリストル−マイヤーズ スクイブ カンパニー 2−アリールグリシンアミド誘導体
WO2010038948A2 (en) * 2008-10-02 2010-04-08 Green Cross Corporation Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
WO2017164575A1 (en) 2016-03-25 2017-09-28 Daewoong Pharmaceutical Co.,Ltd. Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine
KR102081920B1 (ko) * 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Also Published As

Publication number Publication date
WO2018236153A1 (en) 2018-12-27
RS62564B1 (sr) 2021-12-31
CN110582482B (zh) 2022-10-11
MA49472B1 (fr) 2022-01-31
AU2018288933A1 (en) 2019-11-21
CO2019012689A2 (es) 2020-01-17
CA3061713A1 (en) 2018-12-27
CL2019003450A1 (es) 2020-03-27
MY188800A (en) 2022-01-04
US20200181080A1 (en) 2020-06-11
CN110582482A (zh) 2019-12-17
PH12019502865A1 (en) 2020-12-07
JOP20190265A1 (ar) 2019-11-12
MX391715B (es) 2025-03-21
HUE057666T2 (hu) 2022-06-28
EP3642181B1 (en) 2021-11-03
NZ758770A (en) 2022-01-28
KR102233455B1 (ko) 2021-03-29
JP2020519680A (ja) 2020-07-02
ECSP19081847A (es) 2019-11-30
JP6799178B2 (ja) 2020-12-09
BR112019027323A2 (pt) 2020-07-28
EP3642181A1 (en) 2020-04-29
SG11201911164WA (en) 2020-01-30
MA49472A (fr) 2020-04-29
ES2901701T3 (es) 2022-03-23
PT3642181T (pt) 2021-12-20
TN2019000301A1 (en) 2021-05-07
US11345660B2 (en) 2022-05-31
EP3642181A4 (en) 2020-12-09
HRP20211819T1 (hr) 2022-03-04
JOP20190265B1 (ar) 2023-03-28
US20220259146A1 (en) 2022-08-18
KR20180138476A (ko) 2018-12-31
RU2737470C1 (ru) 2020-11-30
AU2018288933B2 (en) 2020-12-10
DOP2019000291A (es) 2019-12-15
SI3642181T1 (sl) 2022-04-29
SA519410407B1 (ar) 2022-06-14
PE20210151A1 (es) 2021-01-26
CA3061713C (en) 2021-10-12

Similar Documents

Publication Publication Date Title
SG11201911164WA (en) Method for preparing intermediate of 4-methoxypyrrole derivative
ZA201908158B (en) Novel method for synthesizing amanitins
GB201502668D0 (en) Method for isolation of polysaccharides
EP3045444A4 (en) Method of preparing vanillin
EP3630722A4 (en) 4-METHOXYPYRROLE DERIVATIVE INTERMEDIATE PREPARATION PROCESS
SI3313853T1 (sl) Postopek za sintezo derivatov rapamicina
SI3717457T1 (sl) Postopek za pripravo enzalutamida z uporabo novega intermediara
HUE049575T2 (hu) Eljárás anilin vagy egy anilin-származék elõállítására
PL3632917T3 (pl) Sposób wytwarzania pochodnych heterocyklicznych
IL293192A (en) Methods for the preparation of indolinobenzodiazepine derivatives
SG11201907182QA (en) Method for producing perfluoroalkadiene compounds
ZA201903463B (en) Method for preparing hexadecahydropyrene
SG11202004021RA (en) Production method for dihydroxyindoles
SG11202003954QA (en) Method for producing dihydroxyindoles
IL260070B (en) A method for the preparation of converted 2-aryl-ethanols
ZA201802897B (en) Preparation method for 2-mercaptobenzothiazole
IL271512B (en) A method for the preparation of modified 4-aminoindan derivatives
IL272811A (en) Thiazole derivative production method
PL3489218T3 (pl) Sposób wytwarzania fenyloaminohydroksyantrachinonów
PT3305790T (pt) Método para preparação de um derivado de imidazol e seu intermediário e forma cristalina
IL273639A (en) A process for the preparation of pyrrolidine alpha-carboxamide derivatives
GB201709297D0 (en) Method for preparing methylprrolidones
HUE060775T2 (hu) Eljárás bisz-pirrolidin vegyületek elõállítására
IL253630B (en) A process for the preparation of modified phenylisoxazoline derivatives
TWI562978B (en) Method for preparation of 1,4-cyclohexanedialkanol